NCT06093841 2025-02-11Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLShanghai Ming Ju Biotechnology Co., Ltd.Phase 2 Active not recruiting46 enrolled